首页 > 最新文献

Current Allergy and Asthma Reports最新文献

英文 中文
Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis.
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2025-02-05 DOI: 10.1007/s11882-025-01192-y
Miguel Rodriguez-Iglesias, Christian Calvo-Henríquez, Daniel Martin-Jimenez, Ainhoa García-Lliberós, Juan Maza-Solano, Ramon Moreno-Luna, Adriana Izquierdo-Domínguez, Gabriel Martínez-Capoccioni, Isam Alobid

Purpose of review: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials.

Recent findings: Significant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms. The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.

{"title":"Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis.","authors":"Miguel Rodriguez-Iglesias, Christian Calvo-Henríquez, Daniel Martin-Jimenez, Ainhoa García-Lliberós, Juan Maza-Solano, Ramon Moreno-Luna, Adriana Izquierdo-Domínguez, Gabriel Martínez-Capoccioni, Isam Alobid","doi":"10.1007/s11882-025-01192-y","DOIUrl":"https://doi.org/10.1007/s11882-025-01192-y","url":null,"abstract":"<p><strong>Purpose of review: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials.</p><p><strong>Recent findings: </strong>Significant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms. The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"13"},"PeriodicalIF":5.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypersensitivity Reactions to Anticonvulsants.
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2025-01-29 DOI: 10.1007/s11882-024-01188-0
Unaiza Faizan, Allison Ramsey

Background: Antiepileptics are the mainstay of treatment for seizure management. Immediate and delayed hypersensitivity reactions associated with antiepileptics are common. It is important to differentiate between these reactions as management and prognosis varies.

Objective: This review article aims to describe the types of hypersensitivity reactions reported with antiepileptics with emphasis on delayed hypersensitivity reactions, as these can be life-threatening.

Methods: Online databases including PubMed and Cochrane were searched, from the inception of the literature to 5/10/24. Studies focusing on hypersensitivity reactions to antiepileptics were reviewed. Case reports, case series, observational studies, and clinical trials were included. Abstracts and studies published in languages other than English were not included.

Results: Immediate reactions can occur with antiepileptics however the incidence is lower than that of delayed hypersensitivity reactions. Delayed hypersensitivity reactions include benign rash as well as severe cutaneous adverse reactions. Acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, Steven Johnson syndrome, and toxic epidermal necrolysis are discussed in detail in this review. We focused on pathogenesis, genetic predisposition, clinical presentation, treatment, and prognosis.

Conclusion: Severe cutaneous adverse reactions can be lethal. It is important to make the correct diagnosis and treat patients accordingly. More studies comparing therapeutic options head-to-head are needed.

{"title":"Hypersensitivity Reactions to Anticonvulsants.","authors":"Unaiza Faizan, Allison Ramsey","doi":"10.1007/s11882-024-01188-0","DOIUrl":"https://doi.org/10.1007/s11882-024-01188-0","url":null,"abstract":"<p><strong>Background: </strong>Antiepileptics are the mainstay of treatment for seizure management. Immediate and delayed hypersensitivity reactions associated with antiepileptics are common. It is important to differentiate between these reactions as management and prognosis varies.</p><p><strong>Objective: </strong>This review article aims to describe the types of hypersensitivity reactions reported with antiepileptics with emphasis on delayed hypersensitivity reactions, as these can be life-threatening.</p><p><strong>Methods: </strong>Online databases including PubMed and Cochrane were searched, from the inception of the literature to 5/10/24. Studies focusing on hypersensitivity reactions to antiepileptics were reviewed. Case reports, case series, observational studies, and clinical trials were included. Abstracts and studies published in languages other than English were not included.</p><p><strong>Results: </strong>Immediate reactions can occur with antiepileptics however the incidence is lower than that of delayed hypersensitivity reactions. Delayed hypersensitivity reactions include benign rash as well as severe cutaneous adverse reactions. Acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, Steven Johnson syndrome, and toxic epidermal necrolysis are discussed in detail in this review. We focused on pathogenesis, genetic predisposition, clinical presentation, treatment, and prognosis.</p><p><strong>Conclusion: </strong>Severe cutaneous adverse reactions can be lethal. It is important to make the correct diagnosis and treat patients accordingly. More studies comparing therapeutic options head-to-head are needed.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"12"},"PeriodicalIF":5.4,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of the Indoor Environment on Childhood Asthma.
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2025-01-27 DOI: 10.1007/s11882-025-01193-x
Ellen R Conroy, Wanda Phipatanakul, Tina M Banzon

Purpose of review: This manuscript reviews the impact of important indoor environmental exposures on pediatric asthma, with a focus on recent literature in the field.

Recent findings: Studies continue to support an association between numerous indoor aeroallergens and air pollutants found in homes and schools and increased asthma morbidity overall. Several recent home and school intervention studies have shown promise, though results have been overall mixed. Indoor environmental exposures contribute to the development of asthma and impact asthma morbidity. Further research is needed to improve our understanding of how to optimize mitigation of these indoor exposures to significantly affect asthma outcomes.

{"title":"The Impact of the Indoor Environment on Childhood Asthma.","authors":"Ellen R Conroy, Wanda Phipatanakul, Tina M Banzon","doi":"10.1007/s11882-025-01193-x","DOIUrl":"https://doi.org/10.1007/s11882-025-01193-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>This manuscript reviews the impact of important indoor environmental exposures on pediatric asthma, with a focus on recent literature in the field.</p><p><strong>Recent findings: </strong>Studies continue to support an association between numerous indoor aeroallergens and air pollutants found in homes and schools and increased asthma morbidity overall. Several recent home and school intervention studies have shown promise, though results have been overall mixed. Indoor environmental exposures contribute to the development of asthma and impact asthma morbidity. Further research is needed to improve our understanding of how to optimize mitigation of these indoor exposures to significantly affect asthma outcomes.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"11"},"PeriodicalIF":5.4,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parosmia: Pathophysiology and Management. 失语症:病理生理学和治疗。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2025-01-16 DOI: 10.1007/s11882-024-01189-z
Xinni Xu, Jerry Hadi Juratli, Basile Nicolas Landis, Thomas Hummel

Purpose of review: Parosmia is a qualitative olfactory disorder in which there is a mismatch between the memory of an odor and the actual experience triggered by an odor. There has been a surge in parosmia-related publications since the COVID-19 pandemic. This review summarizes the latest clinical findings, theories on pathophysiology and potential treatment options.

Recent advances: Potential models of parosmia include peripheral or central hypotheses, which refer to aberrancies in olfactory neuron regeneration or information processing in central olfactory centers respectively. This leads to an incomplete or disorganized pattern of olfactory information relay. Studies using gas chromatography and functional magnetic resonance imaging have identified molecular triggers and intracranial functional connectivity patterns in parosmia respectively. Parosmia tends to occur in a delayed fashion after virus-induced anosmia. It may run a protracted course, but typically improves over time. Currently there are no generally approved, objective ways to ascertain the presence and measure the extent of parosmia. Evidence-based treatment for parosmia remains elusive. In some people, this can lead to health and quality of life issues.

回顾目的:嗅觉缺失症是一种定性嗅觉障碍,其中气味的记忆与气味引发的实际体验之间存在不匹配。自2019冠状病毒病大流行以来,与寄生虫相关的出版物激增。本文综述了最新的临床发现、病理生理学理论和潜在的治疗方案。最新进展:嗅觉缺失的潜在模型包括外周假说和中枢假说,它们分别是指嗅觉神经元再生或中央嗅觉中心信息处理的异常。这导致嗅觉信息传递模式不完整或混乱。通过气相色谱和功能磁共振成像的研究分别确定了腮腺畸形的分子诱因和颅内功能连接模式。在病毒引起的嗅觉缺失之后,嗅觉缺失往往以延迟的方式发生。它可能会持续很长时间,但通常会随着时间的推移而改善。目前还没有被普遍认可的客观的方法来确定是否存在并测量嗅觉缺失的程度。以证据为基础的腮帮子畸形治疗仍然难以捉摸。对一些人来说,这可能会导致健康和生活质量问题。
{"title":"Parosmia: Pathophysiology and Management.","authors":"Xinni Xu, Jerry Hadi Juratli, Basile Nicolas Landis, Thomas Hummel","doi":"10.1007/s11882-024-01189-z","DOIUrl":"https://doi.org/10.1007/s11882-024-01189-z","url":null,"abstract":"<p><strong>Purpose of review: </strong>Parosmia is a qualitative olfactory disorder in which there is a mismatch between the memory of an odor and the actual experience triggered by an odor. There has been a surge in parosmia-related publications since the COVID-19 pandemic. This review summarizes the latest clinical findings, theories on pathophysiology and potential treatment options.</p><p><strong>Recent advances: </strong>Potential models of parosmia include peripheral or central hypotheses, which refer to aberrancies in olfactory neuron regeneration or information processing in central olfactory centers respectively. This leads to an incomplete or disorganized pattern of olfactory information relay. Studies using gas chromatography and functional magnetic resonance imaging have identified molecular triggers and intracranial functional connectivity patterns in parosmia respectively. Parosmia tends to occur in a delayed fashion after virus-induced anosmia. It may run a protracted course, but typically improves over time. Currently there are no generally approved, objective ways to ascertain the presence and measure the extent of parosmia. Evidence-based treatment for parosmia remains elusive. In some people, this can lead to health and quality of life issues.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"10"},"PeriodicalIF":5.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143016861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Food Processing on Allergenicity. 食品加工对致敏性的影响。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2025-01-13 DOI: 10.1007/s11882-024-01191-5
Pablo M Gonzalez, Alison M Cassin, Raquel Durban, Julia E M Upton

Purpose of review: There is an increasing awareness among clinicians that industrial and household food processing methods can increase or decrease the allergenicity of foods. Modification to allergen properties through processing can enable dietary liberations. Reduced allergenicity may also allow for lower risk immunotherapy approaches. This review will equip physicians, nurses, dieticians and other health care providers with an updated overview of the most clinically oriented research in this field. We summarize studies assessing the allergenicity of processed foods through clinically accessible means, such as oral food challenges, skin prick tests, and sIgE levels.

Recent findings: Baking, boiling, canning, fermenting, pasteurizing, peeling, powdering, and roasting heterogenously impact the likelihood of reactivity in egg-, milk-, peanut- and other legume-, tree nut-, fruit-, and seafood-allergic patients. These variations may be due to the use of different temperatures, duration of processing, presence of a matrix, and the specific allergens involved, among other factors. Accurate prediction of tolerance to processed allergens with skin prick tests and sIgE levels remains largely elusive. Food allergy management strategies, especially with milk and egg, have capitalized on the decreased allergenicity of baking. Many milk- and egg-allergic patients tolerate baked and heated forms of these allergens, and the use of these processed foods in oral immunotherapy (OIT) continues to be extensively investigated. Heat is also well recognized to reduce allergic symptoms from some fruits and vegetables in food-pollen syndrome. Other forms of processing such as boiling, fermenting, and canning can reduce allergenicity to a diverse array of foods. Roasting, on the other hand, may increase allergenicity. The application of food processing to food allergy treatments remains largely unexplored by large clinical studies and provides a key avenue for future research. The recognition that food allergy represents a spectrum of hypersensitivity, rather than an all-or-nothing phenomenon, has led to approaches to enable dietary liberation with processed, less-allergenic foods and their use in food allergy immunotherapies.

综述目的:临床医生越来越意识到工业和家庭食品加工方法可以增加或减少食物的致敏性。通过加工改变过敏原的特性可以使饮食释放。降低致敏性也可能允许低风险的免疫治疗方法。这篇综述将使医生、护士、营养师和其他卫生保健提供者对该领域最临床导向的研究有一个最新的概述。我们总结了通过临床手段评估加工食品致敏性的研究,如口腔食物挑战、皮肤点刺试验和sIgE水平。最近的研究发现:烘焙、煮沸、罐装、发酵、巴氏杀菌、去皮、粉末状和烘烤等异质食物会影响对鸡蛋、牛奶、花生和其他豆类、坚果、水果和海鲜过敏的患者产生反应的可能性。这些变化可能是由于使用不同的温度、加工时间、基质的存在以及所涉及的特定过敏原等因素造成的。通过皮肤点刺试验和sIgE水平准确预测对加工过敏原的耐受性在很大程度上仍然难以捉摸。食物过敏管理策略,特别是牛奶和鸡蛋,已经利用烘焙降低过敏原。许多对牛奶和鸡蛋过敏的患者耐受这些过敏原的烘烤和加热形式,并且这些加工食品在口服免疫疗法(OIT)中的使用仍在广泛调查中。热也被认为可以减轻食物花粉综合征中某些水果和蔬菜的过敏症状。其他形式的加工,如煮沸、发酵和罐装,可以减少对各种食物的过敏。另一方面,烘烤可能会增加过敏原。食品加工在食物过敏治疗中的应用在很大程度上尚未得到大型临床研究的探索,这为未来的研究提供了一个关键途径。认识到食物过敏代表了一系列的超敏反应,而不是一种要么全有要么全无的现象,这导致了用加工过的、低致敏性的食物来解放饮食的方法,并将其用于食物过敏免疫疗法。
{"title":"Effects of Food Processing on Allergenicity.","authors":"Pablo M Gonzalez, Alison M Cassin, Raquel Durban, Julia E M Upton","doi":"10.1007/s11882-024-01191-5","DOIUrl":"https://doi.org/10.1007/s11882-024-01191-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>There is an increasing awareness among clinicians that industrial and household food processing methods can increase or decrease the allergenicity of foods. Modification to allergen properties through processing can enable dietary liberations. Reduced allergenicity may also allow for lower risk immunotherapy approaches. This review will equip physicians, nurses, dieticians and other health care providers with an updated overview of the most clinically oriented research in this field. We summarize studies assessing the allergenicity of processed foods through clinically accessible means, such as oral food challenges, skin prick tests, and sIgE levels.</p><p><strong>Recent findings: </strong>Baking, boiling, canning, fermenting, pasteurizing, peeling, powdering, and roasting heterogenously impact the likelihood of reactivity in egg-, milk-, peanut- and other legume-, tree nut-, fruit-, and seafood-allergic patients. These variations may be due to the use of different temperatures, duration of processing, presence of a matrix, and the specific allergens involved, among other factors. Accurate prediction of tolerance to processed allergens with skin prick tests and sIgE levels remains largely elusive. Food allergy management strategies, especially with milk and egg, have capitalized on the decreased allergenicity of baking. Many milk- and egg-allergic patients tolerate baked and heated forms of these allergens, and the use of these processed foods in oral immunotherapy (OIT) continues to be extensively investigated. Heat is also well recognized to reduce allergic symptoms from some fruits and vegetables in food-pollen syndrome. Other forms of processing such as boiling, fermenting, and canning can reduce allergenicity to a diverse array of foods. Roasting, on the other hand, may increase allergenicity. The application of food processing to food allergy treatments remains largely unexplored by large clinical studies and provides a key avenue for future research. The recognition that food allergy represents a spectrum of hypersensitivity, rather than an all-or-nothing phenomenon, has led to approaches to enable dietary liberation with processed, less-allergenic foods and their use in food allergy immunotherapies.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"9"},"PeriodicalIF":5.4,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bronchial Challenge in the Diagnosis of Cannabis Allergy. 支气管挑战在大麻过敏诊断中的作用。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-12-21 DOI: 10.1007/s11882-024-01190-6
Alicia Armentia Medina, Angel San Miguel, Sara Fernández Cortés, Blanca Martín-Armentia, Fernando Pineda

We have read with great interest the recent review published by Dr. Ebo and collaborators on cannabis allergy. It highlights the difficulties in getting a valid diagnosis because some patients do not admit its consumption, which may not be legalized, there are no commercial extracts and there are problems in cutaneous tests interpretation due to cross-reactivity with other related allergens. In addition to this, bronchial challenge is considered the confirmatory diagnosis, but it is complex to perform. This also occurs in diagnosis of occupational asthma, such as in baker's asthma, in which we have investigated a reliable marker to avoid the bronchial challenge. However, we think it is necessary to do this test to ensure a correct etiological diagnosis of cannabis asthma, and we have carried out bronchial challenge with cannabis on more than 600 patients since 2009, all them active consumers. In our country cannabis consumption has not been legalized, but to do this challenges we asked the National Court for permission, which we obtained easily. Although molecular diagnosis has helped in revealing the problems caused by cross-reactivity, the gold standard continues to be the provocation. In our articles we detail how to do it safely, and we encourage our colleagues to reach a definitive diagnosis that cannabis is the cause of their bronchial symptoms.

我们非常感兴趣地阅读了Ebo博士和合作者最近发表的关于大麻过敏的评论。它突出了获得有效诊断的困难,因为一些患者不承认其消费,这可能不合法,没有商业提取物,并且由于与其他相关过敏原的交叉反应,在皮肤测试解释中存在问题。除此之外,支气管挑战被认为是确诊,但执行起来很复杂。这也发生在职业性哮喘的诊断中,例如在贝克氏哮喘中,我们已经研究了一个可靠的标志物来避免支气管挑战。然而,我们认为有必要进行这项测试,以确保大麻哮喘的正确病因诊断,自2009年以来,我们已经对600多名患者进行了大麻支气管挑战,他们都是活跃的消费者。在我国,大麻消费尚未合法化,但为了进行这项挑战,我们向国家法院请求许可,我们很容易获得了许可。虽然分子诊断有助于揭示由交叉反应性引起的问题,但金标准仍然是挑衅。在我们的文章中,我们详细介绍了如何安全地使用它,我们鼓励我们的同事得出一个明确的诊断,大麻是他们支气管症状的原因。
{"title":"Bronchial Challenge in the Diagnosis of Cannabis Allergy.","authors":"Alicia Armentia Medina, Angel San Miguel, Sara Fernández Cortés, Blanca Martín-Armentia, Fernando Pineda","doi":"10.1007/s11882-024-01190-6","DOIUrl":"10.1007/s11882-024-01190-6","url":null,"abstract":"<p><p>We have read with great interest the recent review published by Dr. Ebo and collaborators on cannabis allergy. It highlights the difficulties in getting a valid diagnosis because some patients do not admit its consumption, which may not be legalized, there are no commercial extracts and there are problems in cutaneous tests interpretation due to cross-reactivity with other related allergens. In addition to this, bronchial challenge is considered the confirmatory diagnosis, but it is complex to perform. This also occurs in diagnosis of occupational asthma, such as in baker's asthma, in which we have investigated a reliable marker to avoid the bronchial challenge. However, we think it is necessary to do this test to ensure a correct etiological diagnosis of cannabis asthma, and we have carried out bronchial challenge with cannabis on more than 600 patients since 2009, all them active consumers. In our country cannabis consumption has not been legalized, but to do this challenges we asked the National Court for permission, which we obtained easily. Although molecular diagnosis has helped in revealing the problems caused by cross-reactivity, the gold standard continues to be the provocation. In our articles we detail how to do it safely, and we encourage our colleagues to reach a definitive diagnosis that cannabis is the cause of their bronchial symptoms.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"8"},"PeriodicalIF":5.4,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps. 胸腺基质淋巴生成素(TSLP):呼吸上皮驱动疾病包括慢性鼻窦炎伴鼻息肉的证据。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-12-05 DOI: 10.1007/s11882-024-01186-2
Eugenio De Corso, Peter W Hellings, Wytske J Fokkens, Ludger Klimek, Anju T Peters, Glenis K Scadding, Martin Desrosiers, Stella E Lee, Joaquim Mullol

Purpose of the review: Thymic stromal lymphopoietin (TSLP) is increasingly recognized for its pivotal role in the pathogenesis of various epithelial-driven chronic inflammatory diseases. This review navigates the existing evidence on TSLP, with a particular focus on asthma, before delving into the current understanding of its role in chronic rhinosinusitis with nasal polyps (CRSwNP). We explore the role of TSLP in the pathogenesis of asthma and CRSwNP, two conditions often interconnected and collectively referred to as"Global Airway Disease". Additionally, this review assesses the therapeutic potential of TSLP inhibition as a treatment option for both CRSwNP and asthma. A systematic literature search was conducted; selected publications were used to describe the biology of TSLP, including its expression and diverse effects on inflammation.

Recent findings: The role of TSLP in asthma is well established and supported by the efficacy of tezepelumab, the first anti-TSLP monoclonal antibody approved for both type 2 (T2)-high and T2-low severe asthma. TSLP may be a key contributor to CRSwNP pathogenesis as evidenced by genetic and mechanistic studies in which TSLP has been shown to regulate T2 inflammation and influence non-T2 responses. Preliminary data from the NAVIGATOR trial indicate that tezepelumab may reduce CRSwNP symptoms in patients with comorbid asthma. While further research is required to clarify the extent of TSLP contribution in CRSwNP, this review highlights the potential of anti-TSLP therapies as a novel approach for managing severe, uncontrolled CRSwNP. If these preliminary findings are confirmed, targeting TSLP could become a promising strategy to treat CRSwNP with or without comorbid asthma.

综述的目的:胸腺基质淋巴生成素(TSLP)在各种上皮驱动的慢性炎症性疾病的发病机制中的关键作用越来越被认识到。在深入了解其在慢性鼻窦炎伴鼻息肉(CRSwNP)中的作用之前,本文综述了TSLP的现有证据,特别关注哮喘。我们探讨了TSLP在哮喘和CRSwNP发病机制中的作用,这两种疾病通常相互关联,统称为“全球气道疾病”。此外,本综述评估了TSLP抑制作为CRSwNP和哮喘的治疗选择的治疗潜力。进行了系统的文献检索;选定的出版物用于描述TSLP的生物学,包括其表达和对炎症的多种作用。最近的发现:TSLP在哮喘中的作用已经得到了tezepelumab疗效的支持,tezepelumab是第一个被批准用于2型(T2)高和T2低严重哮喘的抗TSLP单克隆抗体。遗传和机制研究表明,TSLP可能是CRSwNP发病机制的关键因素,其中TSLP已被证明可调节T2炎症并影响非T2反应。NAVIGATOR试验的初步数据表明,tezepelumab可以减轻合并哮喘患者的CRSwNP症状。虽然需要进一步的研究来阐明TSLP在CRSwNP中的作用程度,但这篇综述强调了抗TSLP治疗作为治疗严重、不受控制的CRSwNP的新方法的潜力。如果这些初步发现得到证实,靶向TSLP可能成为治疗伴有或不伴有哮喘的CRSwNP的一种有希望的策略。
{"title":"Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps.","authors":"Eugenio De Corso, Peter W Hellings, Wytske J Fokkens, Ludger Klimek, Anju T Peters, Glenis K Scadding, Martin Desrosiers, Stella E Lee, Joaquim Mullol","doi":"10.1007/s11882-024-01186-2","DOIUrl":"https://doi.org/10.1007/s11882-024-01186-2","url":null,"abstract":"<p><strong>Purpose of the review: </strong>Thymic stromal lymphopoietin (TSLP) is increasingly recognized for its pivotal role in the pathogenesis of various epithelial-driven chronic inflammatory diseases. This review navigates the existing evidence on TSLP, with a particular focus on asthma, before delving into the current understanding of its role in chronic rhinosinusitis with nasal polyps (CRSwNP). We explore the role of TSLP in the pathogenesis of asthma and CRSwNP, two conditions often interconnected and collectively referred to as\"Global Airway Disease\". Additionally, this review assesses the therapeutic potential of TSLP inhibition as a treatment option for both CRSwNP and asthma. A systematic literature search was conducted; selected publications were used to describe the biology of TSLP, including its expression and diverse effects on inflammation.</p><p><strong>Recent findings: </strong>The role of TSLP in asthma is well established and supported by the efficacy of tezepelumab, the first anti-TSLP monoclonal antibody approved for both type 2 (T2)-high and T2-low severe asthma. TSLP may be a key contributor to CRSwNP pathogenesis as evidenced by genetic and mechanistic studies in which TSLP has been shown to regulate T2 inflammation and influence non-T2 responses. Preliminary data from the NAVIGATOR trial indicate that tezepelumab may reduce CRSwNP symptoms in patients with comorbid asthma. While further research is required to clarify the extent of TSLP contribution in CRSwNP, this review highlights the potential of anti-TSLP therapies as a novel approach for managing severe, uncontrolled CRSwNP. If these preliminary findings are confirmed, targeting TSLP could become a promising strategy to treat CRSwNP with or without comorbid asthma.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"7"},"PeriodicalIF":5.4,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
When the Nose Meets the Lab: Histopathological Analysis in Chronic Rhinosinusitis with Nasal Polyps for Routine Clinical Practice. 当鼻子遇到实验室:用于常规临床实践的慢性鼻窦炎伴鼻息肉的组织病理学分析。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-12-01 Epub Date: 2024-10-07 DOI: 10.1007/s11882-024-01180-8
Isam Alobid, Miguel Armengot-Carceller, Mayte Pinilla Urraca, Juan Maza-Solano, Isabel González Guijarro, Sebastián Umbria Jiménez, Pilar San Miguel Fraile, Joaquim Mullol

Purpose of review: We aimed to review the latest evidence regarding the value of tissue histopathological analysis in chronic rhinosinusitis with nasal polyps (CRSwNP) and to facilitate tissue analysis by proposing a pragmatic checklist for clinical settings.

Recent findings: CRSwNP is a chronic inflammatory disease that severely impairs the patient's quality of life. The severity of the disease can be correlated with nasal polyps enriched in eosinophils/IL-5 and, although ≥ 10 eosinophils per high power field are considered enough to determine an eosinophilic CRS, this cut-off value, the biopsy method, and the sampling location are still a matter of debate. Besides, tissue eosinophil values might also have some added value when combined with other cellular counts (e.g., eosinophil-to-lymphocyte ratio, Charcot-Leyden crystals). Structured histopathology analysis of sinonasal tissue-including, for instance, tissue remodelling biomarkers, fibrosis, and eosinophilic aggregates-has proven to be a valuable tool for healthcare professionals to identify different pheno-endotypes of CRSwNP and to improve the prioritisation of candidates to targeted therapies. Patients with CRSwNP are treated according to their severity with corticosteroids (intranasal and systemic), endoscopic sinus surgery, and/or biological therapy. A panel of expert ear, nose, and throat specialists and pathologists proposed a pragmatic checklist to improve the clinical practice around tissue analysis in CRSwNP, to facilitate communication between hospital-based healthcare professionals, and to standardize the evaluation of inflammatory biomarkers.

综述目的:我们旨在回顾有关组织病理学分析在慢性鼻炎伴鼻息肉(CRSwNP)中的价值的最新证据,并通过提出一份适用于临床环境的实用检查表来促进组织分析:最新研究结果:CRSwNP 是一种慢性炎症性疾病,严重影响患者的生活质量。该疾病的严重程度与鼻息肉中富含的嗜酸性粒细胞/IL-5相关,虽然每个高倍视野中嗜酸性粒细胞≥10个足以判定为嗜酸性粒细胞性CRS,但这一临界值、活检方法和取样位置仍存在争议。此外,如果将组织嗜酸性粒细胞值与其他细胞计数(如嗜酸性粒细胞与淋巴细胞比值、Charcot-Leyden 晶体)结合起来,可能会有一些附加价值。事实证明,鼻窦组织的结构组织病理学分析--包括组织重塑生物标志物、纤维化和嗜酸性粒细胞聚集等--是医护人员识别 CRSwNP 不同表型的重要工具,也是改善靶向疗法候选者优先排序的重要工具。CRSwNP 患者可根据其严重程度接受皮质类固醇(鼻内和全身)、内窥镜鼻窦手术和/或生物治疗。一个由耳鼻喉科专家和病理学家组成的专家小组提出了一份实用检查表,以改进围绕 CRSwNP 组织分析的临床实践,促进医院医护人员之间的沟通,并使炎症生物标志物的评估标准化。
{"title":"When the Nose Meets the Lab: Histopathological Analysis in Chronic Rhinosinusitis with Nasal Polyps for Routine Clinical Practice.","authors":"Isam Alobid, Miguel Armengot-Carceller, Mayte Pinilla Urraca, Juan Maza-Solano, Isabel González Guijarro, Sebastián Umbria Jiménez, Pilar San Miguel Fraile, Joaquim Mullol","doi":"10.1007/s11882-024-01180-8","DOIUrl":"10.1007/s11882-024-01180-8","url":null,"abstract":"<p><strong>Purpose of review: </strong>We aimed to review the latest evidence regarding the value of tissue histopathological analysis in chronic rhinosinusitis with nasal polyps (CRSwNP) and to facilitate tissue analysis by proposing a pragmatic checklist for clinical settings.</p><p><strong>Recent findings: </strong>CRSwNP is a chronic inflammatory disease that severely impairs the patient's quality of life. The severity of the disease can be correlated with nasal polyps enriched in eosinophils/IL-5 and, although ≥ 10 eosinophils per high power field are considered enough to determine an eosinophilic CRS, this cut-off value, the biopsy method, and the sampling location are still a matter of debate. Besides, tissue eosinophil values might also have some added value when combined with other cellular counts (e.g., eosinophil-to-lymphocyte ratio, Charcot-Leyden crystals). Structured histopathology analysis of sinonasal tissue-including, for instance, tissue remodelling biomarkers, fibrosis, and eosinophilic aggregates-has proven to be a valuable tool for healthcare professionals to identify different pheno-endotypes of CRSwNP and to improve the prioritisation of candidates to targeted therapies. Patients with CRSwNP are treated according to their severity with corticosteroids (intranasal and systemic), endoscopic sinus surgery, and/or biological therapy. A panel of expert ear, nose, and throat specialists and pathologists proposed a pragmatic checklist to improve the clinical practice around tissue analysis in CRSwNP, to facilitate communication between hospital-based healthcare professionals, and to standardize the evaluation of inflammatory biomarkers.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"657-665"},"PeriodicalIF":5.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy. 伴有鼻息肉的慢性鼻窦炎患者的嗅觉功能障碍:以生物疗法为重点的治疗效果。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-11-26 DOI: 10.1007/s11882-024-01187-1
Josje Janna Otten, Wytske Johanna Fokkens, Sietze Reitsma

Purpose of review: Olfactory dysfunction significantly impacts quality of life that affects a majority of the patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of this review is to explore the impact of various treatment regimens on olfactory dysfunction in patients diagnosed with CRSwNP.

Recent findings: Accurate assessment of olfactory dysfunction remains challenging and should incorporate both psychophysical tests and patient-reported outcomes. Patients with CRSwNP appear capable of reliably evaluating their olfactory function. Standard treatment such as intranasal corticosteroids and surgery have limited capability of restoring the sense of smell. Oral corticosteroids have a far greater potency, albeit short-lived and at the cost of adverse events and side effects. Recent studies on registered biological agents- specifically dupilumab, mepolizumab, and omalizumab- indicate their effectiveness in restoring olfactory function in severe CRSwNP. According to meta-analyses and indirect comparisons, dupilumab shows superiority; however, direct comparative studies are necessary.

综述目的:嗅觉功能障碍严重影响了大多数慢性鼻炎伴鼻息肉(CRSwNP)患者的生活质量。本综述旨在探讨各种治疗方案对确诊为 CRSwNP 患者的嗅觉功能障碍的影响:对嗅觉功能障碍的准确评估仍具有挑战性,应结合心理物理测试和患者报告结果。CRSwNP 患者似乎能够可靠地评估自己的嗅觉功能。鼻内皮质类固醇和手术等标准治疗方法在恢复嗅觉方面的能力有限。口服皮质类固醇的效力要强得多,尽管疗效短暂,但会产生不良反应和副作用。最近对已注册的生物制剂(特别是杜匹单抗、美博利珠单抗和奥马珠单抗)进行的研究表明,它们在恢复严重 CRSwNP 患者的嗅觉功能方面非常有效。根据荟萃分析和间接比较,dupilumab 显示出优越性;然而,直接比较研究是必要的。
{"title":"Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Effect of Treatment with Emphasis on Biological Therapy.","authors":"Josje Janna Otten, Wytske Johanna Fokkens, Sietze Reitsma","doi":"10.1007/s11882-024-01187-1","DOIUrl":"https://doi.org/10.1007/s11882-024-01187-1","url":null,"abstract":"<p><strong>Purpose of review: </strong>Olfactory dysfunction significantly impacts quality of life that affects a majority of the patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of this review is to explore the impact of various treatment regimens on olfactory dysfunction in patients diagnosed with CRSwNP.</p><p><strong>Recent findings: </strong>Accurate assessment of olfactory dysfunction remains challenging and should incorporate both psychophysical tests and patient-reported outcomes. Patients with CRSwNP appear capable of reliably evaluating their olfactory function. Standard treatment such as intranasal corticosteroids and surgery have limited capability of restoring the sense of smell. Oral corticosteroids have a far greater potency, albeit short-lived and at the cost of adverse events and side effects. Recent studies on registered biological agents- specifically dupilumab, mepolizumab, and omalizumab- indicate their effectiveness in restoring olfactory function in severe CRSwNP. According to meta-analyses and indirect comparisons, dupilumab shows superiority; however, direct comparative studies are necessary.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"6"},"PeriodicalIF":5.4,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mast Cells and Mas-related G Protein-coupled Receptor X2: Itching for Novel Pathophysiological Insights to Clinical Relevance. 肥大细胞与 Mas 相关的 G 蛋白偶联受体 X2:瘙痒对临床相关性的新病理生理学启示。
IF 5.4 2区 医学 Q1 ALLERGY Pub Date : 2024-11-25 DOI: 10.1007/s11882-024-01183-5
Mariana Castells, Michael Madden, Carole A Oskeritzian

Purpose of review: Clinical interest in non-IgE activation of mast cells has been growing since the description of the human MRGPRX2 receptor. Its participation in many allergic and inflammatory conditions such as non histaminergic itch, urticaria, asthma and drug hypersensitivity has been growing. We present here an updated review of its structure, expression and biology to help understand conditions and diseases attributed to its activation and/or overpexression and the search for agonists and antagonists of clinical utility.

Recent findings: The description of patients presenting anaphylaxis when exposed to one or multiple MRGPRX2 agonists such as general anesthetics, antibiotics, opiods and other agents has provided evidence of potential heterogeneity in humans. This review provides the most recent developments into the receptor structure, tissue expression and signaling pathways including the potential enhancement of IgE-mediated mast cell activation. New insight into its agonists and antagonists is described and future developments to adress its modulations.

综述的目的:自人类 MRGPRX2 受体被描述以来,临床上对非 IgE 激活肥大细胞的兴趣与日俱增。它在许多过敏性和炎症性疾病(如非组胺过敏性瘙痒症、荨麻疹、哮喘和药物过敏)中的参与度不断提高。我们在此对其结构、表达和生物学进行了最新综述,以帮助理解因其激活和/或过度抑制而导致的病症和疾病,并寻找具有临床实用价值的激动剂和拮抗剂:最近的研究结果:有患者在接触一种或多种 MRGPRX2 激动剂(如全身麻醉剂、抗生素、阿片类药物和其他药物)时出现过敏性休克,这为人类潜在的异质性提供了证据。本综述提供了有关受体结构、组织表达和信号传导途径的最新进展,包括 IgE 介导的肥大细胞活化的潜在增强作用。此外,还介绍了对其激动剂和拮抗剂的新认识,以及解决其调节问题的未来发展。
{"title":"Mast Cells and Mas-related G Protein-coupled Receptor X2: Itching for Novel Pathophysiological Insights to Clinical Relevance.","authors":"Mariana Castells, Michael Madden, Carole A Oskeritzian","doi":"10.1007/s11882-024-01183-5","DOIUrl":"10.1007/s11882-024-01183-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>Clinical interest in non-IgE activation of mast cells has been growing since the description of the human MRGPRX2 receptor. Its participation in many allergic and inflammatory conditions such as non histaminergic itch, urticaria, asthma and drug hypersensitivity has been growing. We present here an updated review of its structure, expression and biology to help understand conditions and diseases attributed to its activation and/or overpexression and the search for agonists and antagonists of clinical utility.</p><p><strong>Recent findings: </strong>The description of patients presenting anaphylaxis when exposed to one or multiple MRGPRX2 agonists such as general anesthetics, antibiotics, opiods and other agents has provided evidence of potential heterogeneity in humans. This review provides the most recent developments into the receptor structure, tissue expression and signaling pathways including the potential enhancement of IgE-mediated mast cell activation. New insight into its agonists and antagonists is described and future developments to adress its modulations.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"5"},"PeriodicalIF":5.4,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Allergy and Asthma Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1